Neue orale Antikoagulantien (NOAK) in der Schlaganfall-Therapie

Kuepper, Clemens; Kellert, Lars; Tiedt, Steffen and Wollenweber, Frank Arne (2018): Neue orale Antikoagulantien (NOAK) in der Schlaganfall-Therapie. In: Fortschritte der Neurologie, Psychiatrie, Vol. 86, No. 2: pp. 117-124

Abstract

Since 2011, new oral anticoagulants (NOAC) can be prescribed for prevention of cardio-embolic ischemic strokes in addition to vitamin K antagonists. NOAC are indicated in patients with non-valvular atrial fibrillation. Although its use is a matter of debate in Germany, the neurological and cardiological societies recommend the use of NOAC over and above vitamin K antagonists due to a better benefit-to-risk ratio attributed to it, especially because of the lower risk of intracranial hemorrhage in NOAC use. A specific antidote is commercially available for the direct thrombin inhibitor dabigatran only. For the factor Xa inhibitors, an antidote is being investigated in clinical trials. To our best knowledge, there are no direct head-to-head studies between the NOACs. Therefore, none of them can be assumed to be superior and the decision for a specific NOAC should be based on the available scientific data from the NOAC trials considering the individual patient's characteristics and comorbidities.

• Item Type: Journal article
• Faculties: Medicine
• Subjects: 600 Technology > 610 Medicine and health
• ISSN: 0720-4299
• Language: German